[Comment] The brim of uncertainty in adjuvant treatment of melanoma

Until recently, standard options for adjuvant melanoma therapy have been limited to interferon- α and ipilimumab, both of which are associated with substantial toxicity and only modest clinical benefit.1–3 2017 was a major year for the adjuvant treatment of melanoma as two new regimens were shown to significantly lower the risk of recurrence in patients with resected, high-risk melanoma. Th e anti-programmed death 1 agent, nivolumab (compared with ipilimumab in the Checkmate 238 study4) and the combination of the RAF and MEK inhibitors, dabrafenib and trametinib (compared with placebo in the COMBI-AD study5) were both shown to improve disease-free survival.

Source: The Lancet Oncology - February 21, 2018 Category: Cancer & Oncology Authors: Allison Betof Warner, Michael A Postow Tags: Comment Source Type: research